JP2009525036A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009525036A5 JP2009525036A5 JP2008552833A JP2008552833A JP2009525036A5 JP 2009525036 A5 JP2009525036 A5 JP 2009525036A5 JP 2008552833 A JP2008552833 A JP 2008552833A JP 2008552833 A JP2008552833 A JP 2008552833A JP 2009525036 A5 JP2009525036 A5 JP 2009525036A5
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- oncolytic
- oncolytic adenovirus
- promoter
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200600216A ES2304281B1 (es) | 2006-02-01 | 2006-02-01 | Adenovirus oncoliticos para el tratamiento del cancer. |
| ESP200600216 | 2006-02-01 | ||
| PCT/ES2007/000050 WO2007088229A1 (es) | 2006-02-01 | 2007-01-31 | Adenovirus oncolíticos para el tratamiento del cáncer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009525036A JP2009525036A (ja) | 2009-07-09 |
| JP2009525036A5 true JP2009525036A5 (https=) | 2012-03-08 |
| JP5075839B2 JP5075839B2 (ja) | 2012-11-21 |
Family
ID=38327139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008552833A Expired - Fee Related JP5075839B2 (ja) | 2006-02-01 | 2007-01-31 | 癌の処置のための腫瘍崩壊性アデノウイルス |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20090311219A1 (https=) |
| EP (1) | EP1990418B1 (https=) |
| JP (1) | JP5075839B2 (https=) |
| CN (1) | CN101484583A (https=) |
| AU (1) | AU2007211434A1 (https=) |
| CA (1) | CA2640528C (https=) |
| ES (1) | ES2304281B1 (https=) |
| WO (1) | WO2007088229A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040175362A1 (en) * | 1999-05-12 | 2004-09-09 | Curiel David T. | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| ES2304281B1 (es) * | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
| US8138318B2 (en) * | 2007-09-13 | 2012-03-20 | Abbott Laboratories | Hepatitis B pre-S2 nucleic acid |
| WO2010097419A1 (en) | 2009-02-25 | 2010-09-02 | Fundació Privada Centre De Regulació Genòmica (Crg) | Conditionally replicating adenovirus effective in the treatment of tumors |
| ES2355882B1 (es) * | 2009-03-24 | 2012-02-13 | INSTITUT CATALÀ D`ONCOLOGIA (Titular al 50%) | Combinación de adenovirus oncolítico y un bloqueador de canal de calcio y su uso para el tratamiento del cáncer. |
| FI123955B (en) * | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| HUE035875T2 (hu) | 2013-10-25 | 2018-06-28 | Psioxus Therapeutics Ltd | Heterológ géneket tartalmazó onkolitikus adenovírusok |
| CN106029889A (zh) * | 2013-11-22 | 2016-10-12 | 德那翠丝有限公司 | 表达免疫细胞刺激受体激动剂的腺病毒 |
| KR102608590B1 (ko) | 2014-09-24 | 2023-12-01 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| HRP20200439T1 (hr) | 2015-04-30 | 2020-06-12 | Psioxus Therapeutics Limited | Onkolitički adenovirus koji kodira protein b7 |
| CN108289920A (zh) * | 2015-10-12 | 2018-07-17 | 汉阳大学校产学协力团 | 用于基因转移和基因治疗的腺病毒复合物 |
| BR112018012180A2 (pt) | 2015-12-17 | 2018-12-04 | Psioxus Therapeutics Ltd | vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| WO2017147269A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| IL303187A (en) | 2016-08-29 | 2023-07-01 | Akamis Bio Ltd | Adenovirus with bispecific T cell activator |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| ES2845690T3 (es) * | 2016-09-12 | 2021-07-27 | Targovax Oy | Combinación de adenovirus e inhibidores de punto de control para el tratamiento del cáncer |
| EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
| SG11202004680UA (en) | 2017-11-22 | 2020-06-29 | Mesoblast Int Sarl | Cellular compositions and methods of treatment i |
| EP3773649A4 (en) | 2018-03-28 | 2022-02-23 | EpicentRx, Inc. | PERSONALIZED CANCER VACCINE |
| CN112292449A (zh) | 2018-04-09 | 2021-01-29 | 萨克生物研究学院 | 具有增强的复制特性的溶瘤腺病毒组合物 |
| US20210340279A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| EP4001404A4 (en) * | 2019-07-16 | 2022-11-02 | Wu, Zetang | VIRUS AND TUMOR THERAPY FOR TARGETED KILLING OF TUMOR CELLS |
| AU2020325825B2 (en) | 2019-08-05 | 2026-02-05 | Mesoblast International Sarl | Cellular compositions comprising viral vectors and methods of treatment |
| CA3188492A1 (en) | 2020-08-10 | 2022-02-17 | Silviu Itescu | Cellular compositions and methods of treatment |
| EP4602078A2 (en) | 2022-10-11 | 2025-08-20 | Yale University | Compositions and methods of using cell-penetrating antibodies |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4147200A (en) * | 1999-12-31 | 2001-07-16 | Chong Kun Dang Pharmaceutical Corp. | Cancer cell-specific gene expression system |
| US6936450B2 (en) * | 2000-04-12 | 2005-08-30 | Compugen Ltd. | Variants of protein kinases |
| US7109029B2 (en) * | 2001-02-23 | 2006-09-19 | Cell Genesys, Inc. | Vector constructs |
| AU2003205465A1 (en) * | 2002-02-19 | 2003-09-09 | The Hospital For Sick Children | Retroviral gene therapy vectors including insulator elements to provide high levels of gene expression |
| US20060147420A1 (en) * | 2004-03-10 | 2006-07-06 | Juan Fueyo | Oncolytic adenovirus armed with therapeutic genes |
| JP2005538697A (ja) * | 2002-04-19 | 2005-12-22 | シエーリング アクチエンゲゼルシャフト | 新規前立腺腫瘍特異的プロモーター |
| ES2304281B1 (es) * | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
| WO2007103825A2 (en) * | 2006-03-02 | 2007-09-13 | The Board Of Regents Of The University Of Texas System | Combination therapy with oncolytic adenovirus |
| AR053246A1 (es) * | 2006-04-28 | 2007-04-25 | Fundacion Inst Leloir | Un fragmento aislado de adn del promotor humano de sparc y su uso para dirigir la expresion de un gen heterologo en celulas tumorales |
| AR053600A1 (es) * | 2006-04-28 | 2007-05-09 | Fundacion Inst Leloir | Un fragmento aislado de adn del promotor humano de a33 y su uso para dirigir la expresion de un gen heterologo en celulas tumorales |
-
2006
- 2006-02-01 ES ES200600216A patent/ES2304281B1/es not_active Expired - Fee Related
-
2007
- 2007-01-31 CA CA2640528A patent/CA2640528C/en not_active Expired - Fee Related
- 2007-01-31 AU AU2007211434A patent/AU2007211434A1/en not_active Abandoned
- 2007-01-31 WO PCT/ES2007/000050 patent/WO2007088229A1/es not_active Ceased
- 2007-01-31 CN CNA2007800091899A patent/CN101484583A/zh active Pending
- 2007-01-31 EP EP07704759A patent/EP1990418B1/en not_active Not-in-force
- 2007-01-31 JP JP2008552833A patent/JP5075839B2/ja not_active Expired - Fee Related
-
2008
- 2008-08-01 US US12/184,881 patent/US20090311219A1/en not_active Abandoned
-
2014
- 2014-07-10 US US14/327,840 patent/US20150071881A1/en not_active Abandoned
-
2016
- 2016-05-02 US US15/144,637 patent/US10016470B2/en not_active Expired - Fee Related
-
2018
- 2018-07-05 US US16/028,037 patent/US20190183946A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009525036A5 (https=) | ||
| US11578104B2 (en) | Adenovirus comprising an albumin-binding moiety | |
| JP7104994B2 (ja) | アデノウイルスおよび対応するプラスミドの作製方法 | |
| JP5075839B2 (ja) | 癌の処置のための腫瘍崩壊性アデノウイルス | |
| McCart et al. | Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes | |
| ES2750305T3 (es) | Mutantes de E1A y E1B de adenovirus selectivos de tumor | |
| Ko et al. | Development of transcriptionally regulated oncolytic adenoviruses | |
| Yaghchi et al. | Vaccinia virus, a promising new therapeutic agent for pancreatic cancer | |
| ES2821876T3 (es) | Promotor bidireccional potente y equilibrado | |
| Poutou et al. | Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model | |
| US20020022018A1 (en) | Tissue-specific self-inactivating gene therapy vector | |
| Park et al. | Adenoviral vector system: a comprehensive overview of constructions, therapeutic applications and host responses | |
| JP2007522797A5 (https=) | ||
| JP4361954B2 (ja) | アデノウィルス核酸を含有する医薬用組成物 | |
| JP2009535031A5 (https=) | ||
| CN103555765A (zh) | 一种转录调控肿瘤靶向复制溶瘤腺病毒载体、携带治疗基因腺病毒及其制备方法和应用 | |
| Gros et al. | Adenovirus release from the infected cell as a key factor for adenovirus oncolysis | |
| CN1328372C (zh) | 肿瘤靶向基因－病毒zd55－il－24及其构建方法和应用 | |
| Nikrad | Development of Novel Therapeutic Approaches for NF1 Deficient Peripheral Nerve Sheath Tumors | |
| AU745600B2 (en) | Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof | |
| Xing et al. | Characterization of cis-acting sequences involved in packaging porcine adenovirus type 3 | |
| Alemany | Molecular design of oncolytic adenoviruses | |
| Deng et al. | Comprehensive genome editing and signaling pathway engineering evolve potent and safe adenoviral producer cell | |
| Fontecedro et al. | Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro | |
| CN121620595A (zh) | 腺病毒载体环状rna表达系统 |